What Sports Illustrated Doesn’t Know May Destroy Your Performance

Sammy Sosa is the next Baseball player to fall to a cloud of suspicion for possibly using banned substances.    After Manny Ramirez got busted for HCG, Sports Illustrated wrote a tabloid hit piece article entitled “What you Don’t Know May Kill You”.   In the article they quote a proclaimed non-expert on a Pro-Hormone called “Monsterdrol”.   “[Mr.] Gonzalez has no background in chemistry or nutritional science.  ” This non-expert says  “If it’s the first time you’re going to be using an anabolic [agent], this stuff is not the way to go.   It’s kind of like trying to light a cigarette with a blowtorch,”

I would put it another way.   Do you want your 16 year old kid driving a Ferrari F40?   Monsterdrol isn’t the demon pill SI tries to make out to be but it is very powerful.   SI says Monsterdrol is a compound that is not listed on the label.    SI offers no proof that the Monsterdrol label is incorrect.    I’m sure if SI did it’s homework they would have pressed the FTC and the FDA to pull Monsterdrol for mislabeled product.   No such thing happened.   In fact Monsterdrol sold out because of the “bad” press.

But always a word of caution with any company you deal with online, you don’t really know what you are buying if the company seems like a “fly by night” company.    Personally I don’t think anyone under 18 should use pro-hormones.    Most guys are producing high amounts of testosterone until their late 20s.   Most guys in their 20s just need to train smarter in order to get the results they are looking for.

Sports Illustrated says that Monsterdrol contains methasteron aka Superdrol.   The Monsterdrol label I found online says it contains 17a-methyl-1, 4-androstadiene-3, 17-diol [an oral Boldenone precursor], 13-ethyl-3-methoxy-gona-2, 5(10)dien-17-one 20 mg [a form of Trenbolone] , 4-hydroxandrostenedione 20mg [an anti-estrogen called Formastat].

Boldenone is popularly known as in an injectable form steriod known as Equipose.   Boldenone is a form of testosterone that doesn’t easily turn into estrogen as much as other testosterones.   Boldenone is a good replacement for Deca-Durabolin. Boldenone’s side-effects are generally mild.   Monsterdrol has an anti-estrogen mixed to counter any estrogen conversion. As per typical any highly androgenic compound can promote oily skin, acne and some conversion to DHT.   DHT can cause prostate problems and male pattern hair loss.

As with any Pro-Hormone cycle it is best to follow it with a Post Cycle Treatment to trigger LH to start producing your own testosterone again.    Just because these compounds are legal doesn’t mean they won’t shut down your own testosterone.

These substances are banned by WADA and is listed on the World Anti-Doping Prohibited List. These substances are legal in the US.

Check with your sports association before consuming this product.
These statements have not been evaluated by the FDA.   This product informantion is not intended to diagnose, treat, cure or prevent disease.

HCG – Human Chorionic Gonadotropin Use After Anabolic Steroid Cycles for Bodybuilding

HCG – Human Chorionic Gonadotropin Use After Anabolic Steroid Cycles for Bodybuilding by George Spellwin

Human Chorionic Gonadotropin (hCG) is a peptide hormone that mimics the action of luteinizing hormone (LH). LH is the hormone that stimulates the testes to produce testosterone. (1) More specifically LH is the primary signal sent from the pituitary to the testes, which stimulates the leydig cells within the testes to produce testosterone.

When steroids are administered, LH levels rapidly decline. The absence of an LH signal from the pituitary causes the testes to stop producing testosterone, which causes rapid onset of testicular degeneration. The testicular degeneration begins with a reduction of leydig cell volume, and is then followed by rapid reductions in intra-testicular testosterone (ITT), peroxisomes, and Insulin-like factor 3 (INSL3) – All important bio-markers and factors for proper testicular function and testosterone production. (2-6,19) However, this degeneration can be prevented by a small maintenance dose of hCG ran throughout the cycle. Unfortunately, most steroid users have been engrained to believe that hCG should be used after a cycle, during PCT. Upon reviewing the science and basic endocrinology you will see that a faster and more complete recovery is possible if hCG is ran during a cycle.

Firstly, we must understand the clinical history of hCG to understand its purpose and its most efficient application. Many popular “steroid profiles” advocate using hCG at a dose of 2500-5000iu once or twice a week. These were the kind of dosages used in the historical (1960’s) hCG studies for hypogonadal men who had reduced testicular sensitivity due to prolonged LH deficiency. (21,22) A prolonged LH deficiency causes the testes to desensitize, requiring a higher hCG dose for ample stimulation. In men with normal LH levels and normal testicular sensitivity, the maximum increase of testosterone is seen from a dose of only 250iu, with minimal increases obtained from 500iu or even 5000iu. (2,11) (It appears the testes maximum secretion of testosterone is about 140% above their normal capacity.) (12-18) If you have allowed your testes to desensitize over the length of a typical steroid cycle, (8-16 weeks) then you would require a higher dose to elicit a response in an attempt to restore normal testicular size and function – but there is cost to this, and a high probability that you won’t regain full testicular function.

One term that is critical to understand is testosterone secretion capacity which is synonymous to testicular sensitivity. This is the amount of testosterone your testes can produce from any given LH or hCG stimulation. Therefore, if you have reduced testosterone secretion capacity (reduced testicular sensitivity), it will take more LH or hCG stimulation to produce the same result as if you had normal testosterone secretion capacity. If you reduce your testosterone secretion capacity too much, then no amount of LH or hCG stimulation will trigger normal testosterone production – and this leads to permanently reduced testosterone production.

To get an idea of how quickly you can reduce your testosterone secretion capacity from your average steroid cycle, consider this: LH levels are rapidly decreased by the 2nd day of steroid administration. (2,9,10) By shutting down the LH signal and allowing the testis to be non-functional over a 12-16 week period, leydig cell volume decreases 90%, ITT decreases 94%, INSL3 decreases 95%, while the capacity to secrete testosterone decreases as much as 98%. (2-6)

Note: visually analyzing testes size is a poor method of judging your actual testicular function, since testicular size is not directly related to the ability to secrete testosterone. (4) This is because the leydig cells, which are the primary sites of testosterone secretion, only make up about 10% of the total testicular volume. Therefore, when the testes may only appear 5-10% smaller, the testes ability to secrete testosterone upon LH or hCG stimulation can actually be significantly reduced to 98% of their normal production. (3-5) The point here is to not judge testosterone secretion capacity by testicular size.

The decreased testosterone secretion capacity caused by steroid use was well demonstrated in a study on power athletes who used steroids for 16 weeks, and were then administered 4500iu hCG post cycle. It was found that the steroid users were about 20 times less responsive to hCG, when compared to normal men who did not use steroids. (8) In other words, their testosterone secretion capacity was dramatically reduced because they did not receive an LH signal for 16 weeks. The testes essentially became desensitized and crippled. Case studies with steroid using patients show that aggressive long-term treatment with hCG at dosages as high as 10,000iu E3D for 12 weeks were unable to return full testicular size. (7) Another study with men using low dose steroids for 6 weeks showed unsuccessful return of Insulin-like factor-3 (INSL3) concentration in the testes upon 5000iu/wk of HCG treatment for 12 weeks (6) (INSL3 is an important biomarker for testosterone production potential and sperm production. 20)

These studies show that postponing hCG usage until the end of a steroid cycle increases your need for a higher dose of hCG, and decreases your odds of a full recovery. As a consequence to using a higher dose of hCG at the end of a cycle, estrogen will be increased disproportionately to testosterone, which then causes further HPTA suppression (from high estrogen) while increasing the risk of gyno. (11) For example, high doses of hCG have been found to raise estradiol up to 165%, while only raising testosterone 140%. (11) Higher doses of hCG are also known to reduce LH receptor concentration and degrade the enzymes responsible for testosterone synthesis within the testes (12,13,19 ) — the last thing someone wants during recovery. While these negative effects of hCG can be partly mitigated by the use of a SERM such as tamoxifen, it will create further problems associated with using a toxic SERM (covered in another article).

In light of the above evidence, it becomes obvious that we must take preventative measures to avoid this testicular degeneration. We must protect our testicular sensitivity. Besides, with hCG being so readily available, and such a painless shot, it makes you wonder why anyone wouldn’t use it on cycle.

Based on studies with normal men using steroids, 100iu HCG administered everyday was enough to preserve full testicular function and ITT levels, without causing desensitization typically associated with higher doses of hCG. (2) It is important that low-dose hCG is started before testicular sensitivity is reduced, which appears to rapidly manifest within the first 2-3 weeks of steroid use. Also, it’s important to discontinue the hCG before you start PCT so your leydig cells are given a chance to re-sensitize to your body’s own LH production. (To help further enhance testicular sensitivity, the dietary supplement Toco-8 may be used)

A more convenient alternative to the above recommendation would be a twice a week shot of 200iu hCG, or possibly a once a week shot of 500iu. However, it is most desirable to adhere to a lower more frequent dose of hCG to mimic the body’s natural LH release and minimize estrogen conversion. If you are starting hCG late in the cycle, one could calculate a rough estimate for their required hCG ‘kick starting’ dosage by multiplying 40iu x days of LH absence, since the testes will be desensitized, thus requiring a higher dose. (ie. 40iu x 60 days = 2400iu HCG dose)

Note: If following the on cycle hCG protocol, hCG should NOT be used for PCT.

For preservation of testicular sensitivity, use 100iu hCG ED starting 7 days after your first AAS dose. At the end of the cycle, drop the hCG two weeks before the AAS clear the system. For example, you would drop hCG about the same time as your last Testosterone Enanthate shot. Or, if you are ending the cycle with orals, you would drop the hCG about 10 days before your last oral dose. This will allow for a sudden and even clearance in hormone levels, while initiating LH and FSH production from the pituitary, to begin stimulating your testes to produce testosterone. Remember, recovery doesn’t begin until you are off hCG since your body will not release its own LH until the hCG has cleared the system.

In conclusion, we have learned that utilizing hCG during a steroid cycle will significantly prevent testicular degeneration. This helps create a seamless transition from “on cycle” to “off cycle” thus avoiding the post cycle crash.

Tren – the Most Popular Pro-Hormone Gets Big, Lean & Cut Results

Tren is a legal cousin to Trenbolone that gets big lean and cut results.  Trenbolone can bind to androgen receptors 300% better than Testosterone.  Tren is a 5a reduced compound so it can NOT to convert to harmful DHT.  Tren is a Progestin and by definition can NOT convert into estrogen.  Tren is known to build high quality muscle.  Tren is known for having a diuretic effect. Tren is also known for increasing the Thyroid hormone T3 leading to more of your calories being burnt by increasing your metabolic rate.

Tren and any pro-hormones should NOT be used by women or anyone under 21 years of age.

Trenbolone has similar strength results as Dianabol, Anapolon 50, and Testosterone.

If Tren is stacked with either TT-40 or Mass it would be a similar stack to Trenbolone & Testosterone.  The results can add up to a lot of muscle gain. Mass is a methylated compound similar to testosterone slowing the breakdown in the liver.  TT-40 is a compound that the body breaks down easier but has a shorter half-life.

If Tren is stacked with AH-89 (legal Stanozolol cousin) similar results may happen when Trenbolone & Stanozolol are combined.  Mega-strength is usually the result of the combination of Trenbolone & Stanozolol.

Using Tren for more than an 8 week cycle is NOT advisable.

Trenbolone is clinically proven to turn your urine rust color because of the unused metabolities leaving your body.

Tren is the most popular pro-hormone because it’s effects are what most men want from a pro-hormone. Lean body mass gains while burning more calories is what most men want. Since Tren is a diuretic it is advisable to drink lots of water while using it.

YouTube Video: Bigger, Stronger, Faster Trailer

If you use Tren during a drug tested sport you will come up positive for using a banned substance.

This substance is banned by the World Anti-Doping Agency

Check with your sports association before consumming this product.
These statements have not been evaluated by the FDA. This product informantion is not intended to diagnose, treat, cure or prevent disease.

Castration NOT ANSWER for Prostate Cancer

Localized prostate cancer rarely helped by hormone therapy – LA Times

“Medical castration to treat such tumors doesn’t extend survival, and its side effects outweigh any potential benefit, a study finds.”

http://www.latimes.com/features/health/la-sci-prostate9-2008jul09,0,4425615.story

http://www.healthnewsreview.org/review/review.php?rid=1391

“The results of the study in question show that at least in this case (older men with localized prostate cancer) that the drive to do something does not necessarily result in doing better. As the story indicated, hormone therapy, like most treatments, is not without important side effects that affect health and quality of life and so its use needs to be considered in terms of the benefit it has been demonstrated to provide.”

Drug Companies cutting back CHEAP Perks

“The U.S. pharmaceutical industry revised its code of conduct, banning gifts to doctors such as pens, mugs and restaurant meals. The changes don’t limit thousands of dollars doctors collect for speaking and consulting.”

The changes are a cosmetic, cheap headline getter while business as usual can keep going full steam ahead. The Drug companies can still hook up their clients with lavish meals in house while doing business as usual.

http://www.bloomberg.com/apps/news?pid=20601202&sid=awty4zXTxepE&refer=healthcare#

The Real Costly Health Care Dilemma

As American Medicine advances further into finding cures for just about everything, fewer and fewer mainstream people can afford these advancements. One powerfully successful cancer drug costs up to $ 100,000 a year but can only extend the lifetime of a cancer patient a few more years. American Medicine is looking more and more like a war between Drug Marketing firms, Doctors who want to save their patients at any cost and the public who want to feel better vs. Insurance companies and Doctors really looking at the cost/benefit ratio.

The cost to develop novel drugs is so high that many drug companies are working to extend the patent rights for their already successful drugs.

Because of the American for profit health care system publically traded drug companies are mandated by their share holders to make the maximum dollars from any drug produced. Until America goes toward a European style National Health care system health care companies will charge as much as the market will bare to keep America healthy.

http://www.nytimes.com/2008/07/06/health/06avastin.html?_r=1&th&emc=th&oref=slogin

Viagra OK For Olympians

The World Anti-Doping Committee has approved Viagra to be used in the Olympic Games. Viagra increases Nitric Oxide and therefore increases oxygen uptake, blood flow and decreases blood pressure.

http://rawstory.com/news/2008/AntiDoping_Agency_Viagra_OK_For_Athletes_0630.html

“If you have more oxygen going to your muscles, that’s more energy and that makes you a better athlete,” said Dr. Andrew McCullough, a sexual health expert at the New York University School of Medicine. “Even if it only gives you a 10 percent increase, in peak athletes that is enough to win.”

Americans Biggest Drug Addicts in World

The United States is number 1 in at least something still.

USA! USA! USA! Gooooo USA! (we’re the awesomest druggies in the world!)
“According to a new survey the USA has highest level of illegal cocaine and cannabis use in the world. Thank goodness the War for Drugs is working so well! Ohh… wait… that’s the war ON drugs and it’s supposed to protect us from ourselves and our nasty drug habits. Well anyway.. here’s the details on the study:”

Toward a Global View of Alcohol, Tobacco, Cannabis, and Cocaine Use: Findings from the WHO World Mental Health Surveys

New Pro-Hormone Ban Almost Here

New Pro-Hormone Ban to go in effect soon.

A long lasting Pro-hormone called Bold increases strength and helps improve endurance will be banned soon.

My personal favorite DMT for strength and protein dependent muscle gains will disappear as well.

Tren is everyone’s overall favorite for bodybuilding muscle gains will be banned as well.

—–

“Boldione is also known by the following chemical name: androsta- 1,4-diene-3,17-dione. DEA has determined that the chemical structure of boldione is chemically related to that of testosterone. The chemical structure of boldione differs from testosterone by only the following two chemical groups: A ketone group at carbon 17 and a double bond between the first and second carbon. The human body would be expected to metabolize the ketone group at carbon 17 into a hydroxyl group that is present on testosterone. Furthermore, the scientific literature reports that the additional double bond at carbon 1 in boldione does not significantly decrease the anabolic activity of the substance (Vida, 1969). Boldione is an anabolic steroid precursor, being metabolized by the body into boldenone (Galletti and Gardi, 1971), which is a schedule III anabolic steroid (21 U.S.C. 801(41)(A)(vi)).

Desoxymethyltestosterone (DMT) is also known by the following names: 17[alpha]-methyl-5a-androst-2-en-17[beta]-ol; and madol. DEA has determined that the chemical structure of desoxymethyltestosterone is chemically related to testosterone. The chemical structure of desoxymethyltestosterone differs from testosterone by the following four chemical features: The lack of a ketone group at the third carbon, a double bond between the second and third carbon, the lack of a double bond between the fourth and fifth carbon, and a methyl group at carbon 17. Each of these four chemical features is known through the scientific literature not to eliminate the anabolic and androgenic activity of the substance (Brueggemeir et al., 2002; Vida, 1969).

19-Nor-4,9(10)-androstadienedione is also known by the following chemical names: 19-norandrosta 4,9(10)-diene-3,17-dione; and estra- 4,9(10)-diene-3,17-dione. DEA has determined that the chemical structure of 19-nor-4,9(10)-androstadienedione is chemically related to testosterone. The chemical structure of 19-nor-4,9(10)- androstadienedione differs from testosterone by the following three chemical groups: A ketone group at carbon 17, the absence of a methyl group at carbon 19, and a double-bond between the ninth and tenth carbon. The human body metabolizes the ketone group at carbon 17 into a hydroxyl group that is present on testosterone. Furthermore, the scientific literature reports that both the absence of the methyl group at carbon 19 and the additional double bond in 19-nor-4,9(10)- androstadienedione increase the anabolic activity of the substance (Vida, 1969). ”

http://www.deadiversion.usdoj.gov/fed_regs/rules/2008/fr0425.htm

Is even NPR owned by Big Pharmaceuticals?

Douglas Kalman makes a great case that even National Public Radio allows uneven handed coverage of the drug debate.

In the quest for more infotainment Marketing and Advertising is being pushed as real science. There aren’t any real hardball questions from real scientists and researchers not involved in profiteering from whatever is being pushed.

—————————————–
conflicts of interest, NPR?
Posted by: “Douglas Kalman” dkalman@miamiresearch.com dougkalman
Wed May 7, 2008 10:25 am (PDT)
medical examiner: Health and medicine explained.

Stealth MarketersAre doctors shilling for drug companies on public
radio?

By Shannon Brownlee and Jeanne Lenzer
Posted Tuesday, May 6, 2008, at 1:06 PM ET

A few weeks ago, devoted listeners of National Public Radio member
stations* were
treated to an episode of the award-winning radio series The Infinite
Mind called “Prozac Nation: Revisited
.” The segment featured four
prestigious medical experts discussing the controversial link between
antidepressants and suicide. In their considered opinions, all four said
that worries about the drugs have been overblown.

The radio show, which was broadcast nationwide and paid for in part by
the John D. and Catherine T. MacArthur Foundation, had the air of quiet,
authoritative credibility. Host Dr. Fred Goodwin, a former director of
the National Institute of Mental Health, interviewed three prominent
guests, and any radio producer would be hard-pressed to find a more
seemingly credible quartet. Credible, that is, except for a crucial
detail that was never revealed to listeners: All four of the experts on
the show, including Goodwin, have financial ties to the makers of
antidepressants. Also unmentioned were the “unrestricted grants” that
The Infinite Mind has received from drug makers, including Eli Lilly,
the manufacturer of the antidepressant Prozac.

We don’t know just how much funding or when the show last received it,
since neither Goodwin nor the show’s producers responded to repeated
requests for interviews. But the larger point is that undisclosed
financial conflicts of interest among media sources seem to be popping
up all over the place these days. Some experts who appear independent
are, in fact, serving as stealth marketers for the drug and biotech
industries, and reporters either don’t know about their sources’
conflicts of interests, or they fail to disclose them to the public.

________________________________

Take the November 2006 NBC Nightly News story that asked, “Can lung
scans really prevent cancer death?” Reporter Mike Taibbi, a former
smoker, underwent scanning by Dr. Claudia Henschke, a professor of
radiology at Weill Cornell Medical College in New York. Henschke claimed
on the show that early detection with lung scans could prevent 80
percent of deaths from lung cancer. Although Taibbi included another
expert who said that Henschke’s claim was “outrageous,” viewers were
left with little way to evaluate the two conflicting viewpoints. And
Taibbi himself concluded that early detection was his “best chance.” At
no point did viewers learn that Henschke’s research was funded by a
tobacco company, which has an investment in making the risks of smoking
appear to be manageable-or that many experts warn that more research is
needed to determine whether the potential benefits of scanning outweigh
its harms.

How frequently are journalists glossing over such conflicts? Gary
Schwitzer, a professor of journalism at the University of Minnesota, is
the publisher of HealthNewsReview.org, a Web site that reviews health
care news for balance, accuracy, and completeness. Schwitzer and his
team of reviewers have looked at 544 stories from top outlets over the
two-year period from April 2006 to April 2008. Journalists had to meet
several criteria in order to receive a satisfactory score, among them:
They had to quote an independent expert-someone not involved in the
relevant research-and they had to make some attempt to report potential
conflicts of interest. Half the stories failed to meet these two
requirements, Schwitzer says.

Conflicts of interest abound even in unexpected places. A recent survey
of
academic medical centers published in the Journal of the American
Medical Association found that 60 percent of academic department chairs
have personal ties to industry-serving as consultants, board members, or
paid speakers, while two-thirds of the academic departments had
institutional ties to industry. Such ties can be extremely lucrative.
And according to these

articles
in the medical
literature, researchers who receive funding from drug and medical-device
manufacturers are up to 3.5 times as likely to conclude their study drug
or medical device works than are researchers without such funding.

An equally clever way for companies to get out their marketing messages
is to go through a consumer group. Drug companies often seed “pharm
teams,” consumer groups that start out as legitimate advocacy
organizations and are subtly manipulated by funding from pharmaceutical
companies to convey the desired talking points. Unless reporters ask
where groups and individual researchers get their money, they have no
idea that their sources may be biased-and neither do their readers,
viewers, and listeners.

Which brings us back to The Infinite Mind and “Prozac Nation:
Revisited,” a show that may stand in a class by itself for concealing
bias. In addition to the show’s unrestricted grants from Lilly, the
host, Goodwin, is on the board of directors of Center for Medicine in
the Public Interest, an industry-funded front, or “Astroturf” group,
which receives a majority of its funding from drug companies. CMPI
President Peter Pitts was one of Goodwin’s three guests for “Prozac
Nation.” We don’t know which companies fund his group because when we
asked him, Pitts said, “I don’t want to go into that.” But CMPI took in
more than $1.4 million in 2006 and, according to its tax forms, spent
$210,000 to influence the media through a large conference, a blog the
group maintains, op-eds published in major newspapers, and multimedia
programs and podcasts. Pitts has another title that might have been
relevant to The Infinite Mind; he is the senior vice president for
global health affairs at the PR firm Manning Selvage & Lee, which
represents Eli Lilly Inc., GlaxoSmithKline, Pfizer, and more than a
dozen other pharmaceutical companies. Yet on the show, Pitts was
identified only by his title as “a former FDA official.”

The second guest on “Prozac Nation,” Andrew F. Leuchter, is a professor
of psychiatry at UCLA who has received research money from drug
companies including Eli Lilly Inc., Pfizer, and Novartis. The third
guest, Nada Stotland, president-elect of the American Psychiatric
Association, has served on the speakers’ bureaus of GlaxoSmithKline and
Pfizer. None of Leuchter and Stotland’s ties to industry was revealed to
listeners-instead, each was introduced as a prominent academic.

The Infinite Mind’s Web site states, “Our independence is perhaps our
greatest asset.” Perhaps, indeed. Neither Goodwin nor the show’s
producers responded to our repeated requests for interviews and queries
about their funding. Pitts, who to his credit did give us an interview,
said he didn’t know why his ties to industry weren’t revealed on the
show. Curious, we tried to learn more about the funding for The Infinite
Mind-and could discover only that the show’s award-winning production
company, Lichtenstein Creative Media, was dissolved by the state of
Massachusetts on March 28 for failing to file a single annual report
since its establishment in 2004.

Some reporters and producers argue that they can’t be expected to ask
every source whether he or she gets money from the drug industry. But
there are obvious first steps to take. A list of academic researchers
who are known to have financial ties to the drug and medical-device
industries is available through the Center for Science in the Public
Interest. (Yes, the name is a lot like the Astroturf group we mentioned
earlier-coincidence?) To be fair, the list is inevitably incomplete, and
Astroturf groups and academics with undeclared financial ties can make
it difficult to ferret out their financial conflicts.

In hopes of making reporters’ jobs a little easier, we’ve created for
journalists an international list of prestigious and independent medical
experts who declare they have no financial ties to drug and device
manufacturers for at least the past five years. We have nearly 100
experts from a wide array of disciplines. E-mail us at
Brownlee.Lenzer@gmail.com , and we’ll
be happy to name names.

Correction, May 6, 2008: The original sentence incorrectly stated that
The Infinite Mind is carried on NPR itself, rather than on NPR member
stations. (Return to
the corrected sentence.)

Douglas S. Kalman PhD, RD, CCRC, FACN

Miami Research Associates

Director, Nutrition & Applied Clinical Research

6141 Sunset Drive #301

Miami, FL. 33143

305-666-2368

305-595-9239 (fax)

http://www.miamiresearch.com